Drug Repositioning¶

Develop a new therapeutic indication for an existing or previously investigated drug by reusing applicable knowledge while generating the indication-specific evidence still required.

Version: v3 · 2026-09-19 · History
Domain-specific #: 1718
Domain group: Applied Sciences & Engineering
Origin domain: Medicine & Healthcare
Subdomain: Drug Discovery and Development → Medicine & Healthcare
Aliases: Drug repurposing, Drug reprofiling, Therapeutic repositioning

Core Idea¶

Drug repositioning is the investigation and development of an existing or previously investigated drug for a therapeutic indication different from the one that motivated its original development or established use. The starting asset may be approved, shelved, discontinued, generic, or clinically investigated. Repositioning reuses whatever is genuinely transferable—chemistry, manufacturing, pharmacokinetics, toxicology, human exposure, or delivery experience—while generating the evidence needed for the new disease, population, dose, route, formulation, combination, and claim.

Candidates can arise serendipitously from clinical observation or systematically from target/pathway knowledge, phenotypic screening, omics signatures, genetics, adverse-event signals, electronic health records, molecular docking, network models, or cross-disease mechanisms.

How would you explain it like I'm…

Old Medicine, New Job

Sometimes a medicine made to help with one sickness turns out to help with a different sickness too. Drug repositioning is when scientists try an old medicine for a new job. They still have to test carefully to be sure it really works and is safe for the new job.

Finding New Uses for Medicines

Drug repositioning means taking a medicine that already exists, or one that was tested before, and developing it to treat a different disease than the one it was made for. Scientists might notice a new use by accident, like a surprising side effect, or search for it on purpose using computers and lab tests. A big advantage is that a lot is already known, like how to make the drug and how the body handles it. But they still need new studies to prove it helps the new disease and to find the right dose for it.

Repurposing Existing Drugs

Drug repositioning is investigating and developing an existing or previously tested drug for a different medical use than the one it was originally developed or approved for. The starting drug might be approved, shelved, discontinued, generic, or tested in trials. Repositioning reuses whatever knowledge truly carries over, such as the chemistry, manufacturing, how the body absorbs and clears it, toxicity data and prior human exposure, while producing new evidence for the new disease, patients, dose, route, formulation and claim. Candidate uses can come from lucky clinical observations or from systematic methods like genetics, screening, health-record analysis or computer modeling. But finding a possible match is only the start; it must still pass scientific, clinical, regulatory, safety and commercial tests.

Drug repositioning is the investigation and development of an existing or previously investigated drug for a therapeutic indication different from the one that motivated its original development or established use. The starting asset can be approved, shelved, discontinued, generic or clinically investigated. The strategy exploits whatever is genuinely transferable, such as chemistry, manufacturing processes, pharmacokinetics, toxicology, human exposure data or delivery experience, while generating new evidence specific to the new disease, population, dose, route, formulation, combination and labeling claim. Candidates arise serendipitously from clinical observation or systematically through target and pathway knowledge, phenotypic screening, omics signatures, genetics, adverse-event signals, electronic health records, molecular docking, network models or shared cross-disease mechanisms. A predicted drug-disease link is only a starting hypothesis and must survive mechanistic, preclinical, clinical, regulatory, manufacturing, safety and commercial evaluation. The defining combination is a preexisting drug asset, a genuinely new therapeutic use, transferable prior evidence, a rationale and validation for the new use, an indication-specific development plan and a regulatory and safety pathway.

Scope of Application¶

Repositioning is used across common, rare, neglected, infectious, oncologic, neurologic, and psychiatric diseases. It is especially attractive where mechanistic overlap exists, human exposure data are available, development resources are constrained, or a shelved compound has a usable safety margin. Sildenafil, thalidomide, and several oncology and rare-disease uses illustrate different routes from observation to new indication.

The strategy can shorten or de-risk parts of development, but savings are conditional. A new route, higher exposure, chronic use, pediatric population, pregnancy context, combination, or formulation may reopen substantial nonclinical and Phase I obligations. Generic availability can also weaken the incentive to fund expensive trials.

Clarity¶

“Existing” must be defined. Some programs restrict the term to approved drugs; others include discontinued or clinical-stage assets. The draft should state asset status and whether “repurposing” and “repositioning” are treated as synonyms.

Reused evidence is not a blanket exemption. Transfer depends on active ingredient, impurities, formulation, route, exposure, population, duration, and endpoint. Regulatory reliance routes such as the U.S.

Manages Complexity¶

Prior knowledge narrows the search and can bypass some early uncertainties. Drug–target–disease networks organize heterogeneous evidence; target product profiles turn a promising observation into explicit requirements; staged validation retires mechanism, exposure, efficacy, safety, and feasibility risks in sequence.

Repositioning also inherits complex history. Published data can be incomplete, shelved-compound records inaccessible, negative results unpublished, and old formulations unavailable.

Abstract Reasoning¶

Define the new clinical need and target product profile.
Establish the asset’s identity, ownership, status, manufacturing route, and prior evidence.
Generate a drug–disease hypothesis through mechanistic or phenotype-linked evidence.
Triangulate the signal across independent data types and rule out artifacts.
Confirm target engagement or phenotypic activity at clinically achievable exposure.
Audit transferable versus nontransferable CMC, PK, toxicology, and trial evidence.

Knowledge Transfer¶

The transferable pattern is to reuse a partially validated asset in a new problem context while explicitly auditing which guarantees survive the transfer. Platform reuse, technology transfer, and case-based design share that logic.

The proposed immediate parent is Translational Research: repositioning is a specialized route for moving biological and clinical evidence into an evaluated therapy.

Relationships to Other Abstractions¶

Current abstraction Drug Repositioning Domain-specific

Parents (1) — outgoing typed relations

Drug Repositioning is a kind of Translational Research Domain-specific

Translational Research is the broader abstraction this entry instantiates.

Hierarchy paths (2) — routes to 2 parentless roots

Drug Repositioning → is a kind of Translational Research → includes Translation and Conceptual Bridging → presupposes Representation → presupposes Abstraction

Show alternative path (1)

Neighborhood in Abstraction Space¶

Drug Repositioning sits in a sparse region of the domain-specific corpus (93^rd percentile for distinctiveness): few abstractions share its structure, so a faithful description tends to retrieve it precisely.

Family — Unclustered & Miscellaneous (2769 abstractions)

Nearest neighbors

Adverse Event Prediction — 0.82
Probability of Success — 0.79
Continuous Individualized Risk Index — 0.79
Diagnostic Method — 0.77
Rule-Based System — 0.77

Computed from structural-signature embeddings · 2026-10-25